Section
Pulmonary artery dilation on chest CT correlates with pulmonary hypertension across chronic lung diseases, with diagnostic accuracy varying by disease subtype.
This review synthesizes evidence comparing diabetes duration and advanced complications between patients undergoing revascularization for lower extremity artery disease (LEAD) and coronary artery disease (CAD), highlighting the heavier diab
The SELECT trial demonstrates semaglutide’s 20% reduction in major cardiovascular events in adults with obesity and cardiovascular disease. Mediation analysis reveals partial but uncertain roles of weight, inflammation, and glycemic m
A phase 2 clinical study demonstrates that lumacaftor safely shortens QTc in LQT2 patients with KCNH2 trafficking defects, supported by patient-specific cardiomyocyte models validating the mechanism.
Declines in frailty, intrinsic capacity, and physical quality of life occur years before cardiovascular events, highlighting a prolonged window for early intervention in older adults.
Atrial fibrillation density, reflecting temporal episode clustering, independently predicts ischaemic stroke risk and improves risk stratification beyond traditional AF burden metrics, enabling more precise stroke prevention strategies.
The EMBOL-AF Global Registry provides comprehensive data on stroke and systemic embolism post-atrial fibrillation ablation, highlighting incidence, timing, risk factors, and procedural impacts alongside evolving ablation strategies and long
Extremely high NT-proBNP levels in hospitalized patients often indicate infection rather than heart failure, with a high mortality risk; interpretation requires comprehensive clinical context.
The ULYSSES trial demonstrates that ultrasound-guided femoral venous puncture markedly lowers vascular access complications compared to conventional palpation-guided techniques in patients undergoing atrial fibrillation ablation, enhancing
This trial evaluated whether atrioventricular node ablation improves outcomes of cardiac resynchronization therapy in heart failure patients with permanent atrial fibrillation, finding no significant benefit over medical rate control.
MTMR4 minor allele homozygosity influences arrhythmic risk oppositely in LQT1 and LQT2, providing critical insights for personalized risk stratification in long QT syndrome patients.
Left atrial mechanical dysfunction, particularly atrial electromechanical dissociation and impaired left atrial strain contraction, forecasts increased cerebrovascular events in transthyretin amyloid cardiomyopathy patients even in sinus rh
The EXCALIBUR study reveals significant arrhythmia incidence in cardiac amyloidosis (CA), highlighting subtype-specific arrhythmic profiles linked to myocardial amyloid burden, guiding risk stratification and management.
This study reveals that lifelong genetic differences in LDL cholesterol levels do not significantly affect the risk of venous thromboembolism (VTE), suggesting LDL-C may not be a major causal factor in VTE development.
This large nationwide study demonstrates that coronary CTA-derived FFR-CT strongly predicts future myocardial infarction, cardiovascular death, and revascularization, independent of traditional risk factors and stenosis severity, with a thr
This article examines the real-world safety and efficacy of the extravascular implantable cardioverter defibrillator (EV-ICD) over 1 year, demonstrating effective arrhythmia management and an acceptable safety profile in a large, global pat
Sotatercept improves right heart mechanics in patients with pulmonary arterial hypertension by decreasing right ventricular afterload and contractility in a balanced manner, enhancing right ventricular free wall function and right atrial pe
A phase 2 randomized trial found that ilofotase alfa did not significantly reduce kidney injury or improve outcomes in high-risk patients undergoing on-pump cardiac surgery, though it was safe and well tolerated.
A nationwide survey of hospitalists reveals varied beliefs regarding treatment thresholds and approaches for asymptomatic elevated blood pressure in hospitalized patients, highlighting clinical uncertainty and practice variation.
Empagliflozin consistently reduces major cardiovascular events, heart failure hospitalizations, and mortality across diverse sociodemographic and cardiovascular risk groups in older adults with type 2 diabetes, with especially pronounced ab
